Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 2: Line 2:
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
|-
|-
!Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review
!Disease (5th Edition)!!Page Type!!Author (5th edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Author Content (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes
!Correlated Prior Disease Name (4th Edition)!!Notes
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
Line 10: Line 11:
|
|
----<br />
----<br />
|
|
|
|
|
Line 19: Line 21:
|
|
|-
|-
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)||
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
| ||
|
|
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR||
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR||
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR||
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR||
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR||
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR||
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR||
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR||
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR||
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR||
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR||
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR||
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR||
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR||
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR||
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR||
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR||
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR||
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR||
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR||
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR||
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR||
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR||
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR||
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR||
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR||
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
| ||
|
|
|-
|-
|Acute promyelocytic leukaemia with PML::RARA fusion
|Acute promyelocytic leukaemia with PML::RARA fusion
Line 123: Line 157:
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|
|
|
|
Line 135: Line 170:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 147: Line 183:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 159: Line 196:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 171: Line 209:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 183: Line 222:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 195: Line 235:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 207: Line 248:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 219: Line 261:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 231: Line 274:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 243: Line 287:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 255: Line 300:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 267: Line 313:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 279: Line 326:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 291: Line 339:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 303: Line 352:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 315: Line 365:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 327: Line 378:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 339: Line 391:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 351: Line 404:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 363: Line 417:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 375: Line 430:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 387: Line 443:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 399: Line 456:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 411: Line 469:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 423: Line 482:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 435: Line 495:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 447: Line 508:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 459: Line 521:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 471: Line 534:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 483: Line 547:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 495: Line 560:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 507: Line 573:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 516: Line 583:
|
|
----<br />
----<br />
|
|
|
|
|
Line 533: Line 601:
|
|
|Greg Corboy (GC)
|Greg Corboy (GC)
|
|
|
|
|
Line 545: Line 614:
|
|
|GC
|GC
|
|
|
|
|
Line 557: Line 627:
|
|
|GC
|GC
|
|
|
|
|
Line 569: Line 640:
|
|
|GC
|GC
|
|
|
|
|
Line 581: Line 653:
|
|
|GC
|GC
|
|
|
|
|
Line 593: Line 666:
|
|
|GC
|GC
|
|
|
|
|
Line 605: Line 679:
|
|
|GC
|GC
|
|
|
|
|
Line 617: Line 692:
|
|
|GC
|GC
|
|
|
|
|
Line 629: Line 705:
|
|
|GC
|GC
|
|
|
|
|
Line 641: Line 718:
|
|
|GC
|GC
|
|
|
|
|
Line 653: Line 731:
|
|
|GC
|GC
|
|
|
|
|
Line 662: Line 741:
|
|
----<br />
----<br />
|
|
|
|
|
Line 679: Line 759:
|
|
|GC
|GC
|
|
|
|
|
Line 691: Line 772:
|
|
|GC
|GC
|
|
|
|
|
Line 703: Line 785:
|
|
|GC
|GC
|
|
|
|
|
Line 715: Line 798:
|
|
|GC
|GC
|
|
|
|
|
Line 727: Line 811:
|
|
|GC
|GC
|
|
|
|
|
Line 739: Line 824:
|
|
|Holli Drendel (HD)
|Holli Drendel (HD)
|
|
|
|
|
Line 751: Line 837:
|
|
|HD
|HD
|
|
|
|
|
Line 763: Line 850:
|
|
|HD
|HD
|
|
|
|
|
Line 775: Line 863:
|
|
|HD
|HD
|
|
|
|
|
Line 787: Line 876:
|
|
|HD
|HD
|
|
|
|
|
Line 799: Line 889:
|
|
|HD
|HD
|
|
|
|
|
Line 811: Line 902:
|
|
|HD
|HD
|
|
|
|
|
Line 823: Line 915:
|
|
|HD
|HD
|
|
|
|
|
Line 835: Line 928:
|
|
|HD
|HD
|
|
|
|
|
Line 847: Line 941:
|
|
|HD
|HD
|
|
|
|
|
Line 859: Line 954:
|
|
|HD
|HD
|
|
|
|
|
Line 871: Line 967:
|
|
|HD
|HD
|
|
|
|
|
Line 883: Line 980:
|
|
|HD
|HD
|
|
|
|
|
Line 895: Line 993:
|
|
|HD
|HD
|
|
|
|
|
Line 900: Line 999:
|-
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
| ||
|
|
|
| ||
|-
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG||
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
| ||
|
|
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
| ||
|
|
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
| ||
|
|
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG||
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
| ||
|
|
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
Line 923: Line 1,027:
|
|
|SG
|SG
|
|
|
|
|
Line 935: Line 1,040:
|
|
|SG
|SG
|
|
|
|
|
Line 947: Line 1,053:
|
|
|SG
|SG
|
|
|
|
|
Line 959: Line 1,066:
|
|
|SG
|SG
|
|
|
|
|
Line 971: Line 1,079:
|
|
|SG
|SG
|
|
|
|
|
Line 983: Line 1,092:
|
|
|SG
|SG
|
|
|
|
|
Line 995: Line 1,105:
|
|
|SG
|SG
|
|
|
|
|
Line 1,007: Line 1,118:
|
|
|SG
|SG
|
|
|
|
|
Line 1,019: Line 1,131:
|
|
|SG
|SG
|
|
|
|
|
Line 1,031: Line 1,144:
|
|
|SG
|SG
|
|
|
|
|
Line 1,043: Line 1,157:
|
|
|SG
|SG
|
|
|
|
|
Line 1,055: Line 1,170:
|
|
|SG
|SG
|
|
|
|
|
Line 1,067: Line 1,183:
|
|
|SG
|SG
|
|
|
|
|
Line 1,079: Line 1,196:
|
|
|SG
|SG
|
|
|
|
|
Line 1,091: Line 1,209:
|
|
|SG
|SG
|
|
|
|
|
|
|
|-
|-
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
| ||
|
|
|-
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC||
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
| ||
|
|
|-
|-
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC||
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC||
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
| ||
|
|
|-
|-
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC||
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC||
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC||
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC||
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC||
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC||
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC||
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC||
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC||
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC||
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC||
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC||
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC||
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC||
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC||
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
| ||
|
|
|-
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC||
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC||
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC||
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC||
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
| ||
|
|
|-
|-
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC||
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
| ||
|
|
|-
|-
|Cold agglutinin disease
|Cold agglutinin disease
Line 1,190: Line 1,338:
|
|
|SG
|SG
|
|
|
|
|
|
|
|-
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG||
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
| ||
|
|
|-
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG||
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
| ||
|
|
|-
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Mu heavy chain disease||Disease|| || || || || ||SG
|Mu heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
|Alpha heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Plasmacytoma||Disease|| || || || || ||SG
|Plasmacytoma||Disease|| || || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
| ||
|
|
|
| ||
|-
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
| ||
|
|
|
| ||
|-
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Line 1,241: Line 1,401:
|
|
----<br />
----<br />
|
|
|
|
|
Line 1,251: Line 1,412:
|-
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
|
|
|
| ||
|-
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK||
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK||
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD||
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
| ||
|
|
|-
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
|Early T-precursor lymphoblastic leukaemia / lymphoma
Line 1,271: Line 1,436:
|
|
|HD
|HD
|
|
|
|
|
Line 1,283: Line 1,449:
|
|
|SK
|SK
|
|
|
|
|
|
|
|-
|-
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK||
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
| ||
|
|
|-
|-
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK||
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK||
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK||
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK||
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK||
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK||
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK||
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK||
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK||
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK||
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK||
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK||
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK||
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK||
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK||
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
| ||
|
|
|-
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK||
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK||
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK||
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK||
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK||
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK||
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
| ||
|
|
|-
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK||
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK||
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK||
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SK||
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK||
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK||
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
| ||
|
|
|-
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
| ||
|
|
|-
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
Line 1,391: Line 1,591:
|
|
----<br />
----<br />
|
|
|
|
|
Line 1,408: Line 1,609:
|
|
|GC
|GC
|
|
|
|
|
Line 1,420: Line 1,622:
|
|
|GC
|GC
|
|
|
|
|
Line 1,432: Line 1,635:
|
|
|GC
|GC
|
|
|
|
|
Line 1,444: Line 1,648:
|
|
|GC
|GC
|
|
|
|
|
Line 1,456: Line 1,661:
|
|
|GC
|GC
|
|
|
|
|
Line 1,468: Line 1,674:
|
|
|GC
|GC
|
|
|
|
|
Line 1,480: Line 1,687:
|
|
|GC
|GC
|
|
|
|
|
Line 1,489: Line 1,697:
|
|
----<br />
----<br />
|
|
|
|
|
Line 1,498: Line 1,707:
|
|
|-
|-
|Fanconi anaemia||Disease|| || || || || ||NA||
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
| ||
|
|
|-
|-
|Bloom syndrome||Disease|| || || || || ||NA||
|Bloom syndrome||Disease|| || || || || ||NA|| ||
| ||
|
|
|-
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA||
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
| ||
|
|
|-
|-
|RASopathies||Disease|| || || || || ||NA||
|RASopathies||Disease|| || || || || ||NA|| ||
| ||
|
|
|}
|}
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"